newsfilter
← Earnings
Earnings Releases·

Madrigal Pharmaceuticals — Third Quarter 2026 Earnings Summary

Madrigal Pharmaceuticals reported third-quarter 2026 net sales of $431.3 million for Rezdiffra, marking a 50% year-over-year increase and achieving its first quarter of profitability with year-to-date sales exceeding $1.1 billion. As of September 30, 2026, the company treated over 55,850 patients and held $961.8 million in cash and marketable securities. The company also announced the initiation of the MAESTRO-CSPH Phase 3 trial for MASH cirrhosis and the appointment of John C. Reed, M.D., Ph.D., to its Board of Directors.

Company
MADRIGAL PHARMACEUTICALS INC
Sector
Healthcare
Industry
Biotechnology